房颤血液透析患者的华法林使用:全国性人群研究
该研究基于韩国全国医保数据库,纳入9974例房颤血液透析患者,其中29.3%使用华法林。经倾向评分匹配分析,华法林使用与出血性卒中风险增加显著相关(HR 1.44,95%CI 1.09-1.91),而未显著降低缺血性卒中风险。提示血透房颤患者使用华法林需谨慎。
要点
- 房颤血透患者华法林使用率29.3%,出血性卒中风险增加44%。
- 倾向匹配后华法林与出血性卒中风险增加独立相关(HR 1.56)。
- 华法林未显著降低缺血性卒中风险,需权衡利弊。
核心结论
- 房颤血液透析患者使用华法林与出血性卒中风险增加相关,且未能预防血栓栓塞并发症。
研究设计与样本
- 基于韩国健康保险审查评估院2009-2013年全国强制医保数据库的回顾性人群研究。
- 共纳入9974例房颤血液透析患者,平均年龄66.6±12.2岁,男性5806例(58.2%)。
主要发现
- 华法林使用者2921例(29.3%),平均随访15.9±11.1个月。
- 缺血性卒中和出血性卒中分别发生678例(6.8%)和227例(2.3%)。
- 总体队列中,华法林与出血性卒中风险增加显著相关(HR 1.44,95%CI 1.09-1.91,P=0.010)。
- 倾向匹配队列中,华法林与出血性卒中风险增加显著相关(HR 1.56,95%CI 1.10-2.22,P=0.013)。
- 缺血性卒中风险在倾向匹配队列(HR 0.95,95%CI 0.78-1.15,P=0.569)和总体队列(HR 1.06,95%CI 0.90-1.26,P=0.470)均无显著差异。
临床怎么用
- 对房颤血液透析患者处方华法林时应充分评估出血风险,并密切监测。
- 不能依赖华法林来预防该类患者的血栓栓塞并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The aim of this study is to elucidate the effects of warfarin use in patients with atrial fibrillation undergoing dialysis using a population-based Korean registry. METHODS: Data were extracted from the Health Insurance Review and Assessment Service, which is a nationwide, mandatory social insurance database of all Korean citizens enrolled in the National Health Information Service between 2009 and 2013. Thromboembolic and hemorrhagic outcomes were analyzed according to warfarin use. Overall and propensity score-matched cohorts were analyzed by Cox proportional hazards models. RESULTS: Among 9974 hemodialysis patients with atrial fibrillation, the mean age was 66.6±12.2 years, 5806 (58.2%) were men, and 2921 (29.3%) used warfarin. After propensity score matching to adjust for all described baseline differences, 5548 subjects remained, and differences in baseline variables were distributed equally between warfarin users and nonusers. During a mean follow-up duration of 15.9±11.1 months, ischemic and hemorrhagic stroke occurred in 678 (6.8%) and 227 (2.3%) patients, respectively. In a multiple Cox model, warfarin use was significantly associated with an increased risk of hemorrhagic stroke (hazard ratio, 1.44; 95% confidence interval, 1.09-1.91; P=0.010) in the overall cohort. Furthermore, a significant relationship between warfarin use and hemorrhagic stroke was found in propensity-matched subjects (hazard ratio, 1.56; 95% confidence interval, 1.10-2.22; P=0.013). However, the ratios for ischemic stroke were not significantly different in either the propensity-matched (hazard ratio, 0.95; 95% confidence interval, 0.78-1.15; P=0.569) or overall cohort (hazard ratio, 1.06; 95% confidence interval, 0.90-1.26; P=0.470). CONCLUSIONS: Our findings suggest that warfarin should be used carefully in hemodialysis patients, given the higher risk of hemorrhagic events and the lack of ability to prevent thromboembolic complications.
引用
- Yoon CY, Noh J, Jhee JH, et al. Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study. Stroke. 2017. PMID: 28801476. doi:10.1161/STROKEAHA.117.017114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。